From Aristos we want to congratulate our client, the Spanish company AbilityPharma, for having won the January call, the first in 2020, of the EIC Accelerator (formerly SME Instrument Phase 2) with its PanC-ASAP project, the first pancreatic cancer solution as an oral anticancer compound.
AbilityPharma has won in the Grant + Equity modality, which is an option that can be accessed only since the past call of October 2019.
The project will probably start in June 2020 and will last 30 months.
We are very pleased to have been part of this success of AbilityPharma, and we wish them the best of luck in developing this fantastic project, which will extend the lives of so many people.
Follow us on Twitter.